M0221 Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency

Short descriptor: Tixagev and cilgav inj hm

⚠ Terminated HCPCS Level II 2026
Terminated Code
M0221 was terminated as of 2024-12-12 and should not be reported for dates of service after that date. This page is retained for historical reference.
Open M0221 in the app →

Look up M0221 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.

M0221 is the HCPCS Level II code for Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency (2026). It belongs to Section M — Medical Services. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Vaccinations.

Classification & CMS Attributes

Medicare Coverage
Carrier judgment (code C)
Part B Pricing
Vaccinations (indicator 54)
Type of Service
Pneumococcal/flu/hepatitis B vaccine
Effective Date
2024-12-13
Termination Date
2024-12-12
2026 Maintenance
No change this year

References

Cite This Page

Reference M0221 with the canonical source and edition:

M0221 — Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/M0221

Canonical URL: https://icd10codingpro.com/hcpcs-codes/M0221

Related Codes in Section M

Browse all HCPCS Level II sections →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2026-01-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial